Moderna’s (MRNA) stock gains on COVID-19 vaccine approval from the European Commission
Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the European Commission for its COVID-19…
30 articles, transcripts, and reports
Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the European Commission for its COVID-19…
Shares of Moderna Inc. (NASDAQ: MRNA) were up over 8% in morning trade on Monday as the company reported positive results from its clinical study…
Moderna Inc. (NASDAQ: MRNA) Q3 2020 earnings call dated Oct. 29, 2020 Corporate Participants: Lavina Talukdar — Senior Vice President & Head of Investor Relations Stephane Bancel — Chief…
Shares of Moderna Inc. (NASDAQ: MRNA) have gained 246% since the beginning of this year and more than 279% over the past 52 weeks. The…
Moderna Inc. (NASDAQ: MRNA) Q2 2020 earnings call dated Aug. 05, 2020 Corporate Participants: Lavina Talukdar — Head of Investor Relations Stephane Bancel — Chief Executive Officer Tal Zaks — Chief…
Moderna Inc (NASDAQ: MRNA) Moderna Vaccine Against COVID-19 Phase 1 Interim Results Publication Call dated July 15, 2020 Corporate Participants: Lavina Talukdar — Head of Investor Relations…
Moderna Inc (MRNA) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Lavina Talukdar — Head of Investor Relations Stephane Bancel — Chief Executive Officer Tal Zaks — Chief Medical…
Moderna Inc (MRNA) Q1 2019 interim phase 1 data conference call dated May. 18, 2020 Corporate Participants: Lavina Talukdar — Head of Investor Relations Stephane Bancel — Chief Executive…
The entire world is waiting for some good news on a vaccine for the novel coronavirus. So far the global pandemic has claimed more than…
Shares of Moderna Inc. (NASDAQ: MRNA) soared to a record high of $29.98 on Wednesday after shipping the first coronavirus vaccine candidate to the National…